SK8599A3 - Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal - Google Patents

Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal Download PDF

Info

Publication number
SK8599A3
SK8599A3 SK85-99A SK8599A SK8599A3 SK 8599 A3 SK8599 A3 SK 8599A3 SK 8599 A SK8599 A SK 8599A SK 8599 A3 SK8599 A3 SK 8599A3
Authority
SK
Slovakia
Prior art keywords
carbon atoms
alkylene
group
formula
compound
Prior art date
Application number
SK85-99A
Other languages
English (en)
Slovak (sk)
Inventor
Jeffrey M Dener
Elaine Yee-Lin Kuo
Ken D Rice
Vivian R Wang
Wendy B Young
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of SK8599A3 publication Critical patent/SK8599A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK85-99A 1996-07-30 1997-07-30 Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal SK8599A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US89577297A 1997-07-17 1997-07-17
PCT/US1997/013422 WO1998004537A1 (en) 1996-07-30 1997-07-30 Novel compounds and compositions for treating diseases associated with tryptase activity

Publications (1)

Publication Number Publication Date
SK8599A3 true SK8599A3 (en) 2000-03-13

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
SK85-99A SK8599A3 (en) 1996-07-30 1997-07-30 Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal

Country Status (17)

Country Link
EP (1) EP0934293A1 (lv)
JP (1) JP2001509787A (lv)
KR (1) KR20000029679A (lv)
CN (1) CN1073103C (lv)
AU (1) AU733621B2 (lv)
CA (1) CA2262542A1 (lv)
CZ (1) CZ29799A3 (lv)
EE (1) EE9900036A (lv)
FI (1) FI990171A (lv)
HU (1) HUP0003267A3 (lv)
LV (1) LV12291B (lv)
NO (1) NO990433L (lv)
NZ (1) NZ333713A (lv)
PL (1) PL331465A1 (lv)
SI (1) SI9720047A (lv)
SK (1) SK8599A3 (lv)
WO (1) WO1998004537A1 (lv)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
JP2002502845A (ja) * 1998-02-06 2002-01-29 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ トリプターゼ阻害物質
US6489327B1 (en) * 1998-02-06 2002-12-03 Max-Planck-Gesellschaft Zur Fordrungder Wisenschaften, E.V. Tryptase inhibitors
CA2342855A1 (en) * 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyranoses
AU777026B2 (en) * 1999-08-10 2004-09-30 Altana Pharma Ag Novel tryptase inhibitors
WO2001019809A1 (en) * 1999-09-14 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
AU1413301A (en) * 1999-11-17 2001-05-30 Sumitomo Pharmaceuticals Company, Limited Diabetic remedy containing dipiperazine derivative
DE19955476A1 (de) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE60011677T2 (de) * 1999-12-20 2005-07-14 Altana Pharma Ag Tryptase-inhibitoren
ATE268322T1 (de) 1999-12-20 2004-06-15 Altana Pharma Ag Inhibitoren der tryptase
US6924305B2 (en) 2001-01-31 2005-08-02 Altana Pharma Ag Diazocine derivatives and their use as tryptase inhibitors
WO2002066420A2 (en) * 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
DE60217076T2 (de) 2001-02-21 2007-06-21 Altana Pharma Ag Tryptaseinhibitoren
AU2002254941B2 (en) * 2001-03-15 2007-05-17 Altana Pharma Ag Tryptase-inhibitors
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
KR100958552B1 (ko) 2001-06-11 2010-05-17 제노포트 인코포레이티드 Gaba 유사체의 프로드러그, 이의 조성물 및 용도
AU2002314165B2 (en) 2001-06-19 2008-02-21 Altana Pharma Ag Tryptase inhibitors
CN102429882B (zh) 2004-11-04 2015-03-25 什诺波特有限公司 加巴喷丁前体药物持续释放口服剂型
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之1-胺基-烷基環己烷衍生物類
CN102159201A (zh) 2008-12-19 2011-08-17 莫茨药物股份两合公司 用于治疗肥大细胞介导的疾病的1-氨基-烷基环己烷衍生物
FR3038605B1 (fr) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
JP7373191B2 (ja) * 2017-05-12 2023-11-02 国立研究開発法人理化学研究所 クラスa gpcr結合性化合物改変体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
CZ289930B6 (cs) * 1993-03-12 2002-04-17 Axys Pharmaceuticals, Inc. Arylové a heteroarylové peptidové deriváty a farmaceutické prostředky je obsahující
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
WO1995032945A1 (en) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
CN1160398A (zh) * 1994-09-23 1997-09-24 阿瑞斯药物公司 治疗肥大细胞炎性疾病的组合物和方法
PL322409A1 (en) * 1995-03-24 1998-01-19 Arris Pharm Corp Reversible protease inhibitors
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Also Published As

Publication number Publication date
CA2262542A1 (en) 1998-02-05
CN1226892A (zh) 1999-08-25
SI9720047A (sl) 1999-08-31
LV12291B (lv) 2000-04-20
FI990171A0 (fi) 1999-01-29
CN1073103C (zh) 2001-10-17
KR20000029679A (ko) 2000-05-25
PL331465A1 (en) 1999-07-19
AU3967097A (en) 1998-02-20
AU733621B2 (en) 2001-05-17
HUP0003267A3 (en) 2002-02-28
FI990171A (fi) 1999-03-23
NO990433D0 (no) 1999-01-29
EE9900036A (et) 1999-08-16
HUP0003267A2 (hu) 2001-06-28
JP2001509787A (ja) 2001-07-24
EP0934293A1 (en) 1999-08-11
WO1998004537A1 (en) 1998-02-05
NZ333713A (en) 2000-12-22
LV12291A (lv) 1999-06-20
CZ29799A3 (cs) 1999-06-16
NO990433L (no) 1999-03-25

Similar Documents

Publication Publication Date Title
SK8599A3 (en) Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal
AU721247B2 (en) Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
CZ87097A3 (en) Preparation for therapy and therapeutical methods for treating inflammations mediated by mast cells
US20070179150A1 (en) Nitrosated proton pump inhibitors, compositions and methods of use
SK17312001A3 (sk) Inhibítory metaloproteázy
WO2000027826A1 (de) Neue pyrimidine, deren herstellung und verwendung
ZA200607752B (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase
JP2003509417A (ja) トリプターゼインヒビター
WO2000014097A2 (de) Neue pyranosen
US7015325B2 (en) Tryptase inhibitors
DE102007010815B3 (de) Meta-substituierte Phenylsulfonylamide sekundärer Aminosäureamide, ihre Herstellung und Verwendung als Hemmstoffe der Matriptase
AU777026B2 (en) Novel tryptase inhibitors
US6815557B2 (en) Tryptase inhibitors
LT4587B (lt) Nauji junginiai ir kompozicijos, skirti gydyti ligas, susijusias su triptazės aktyvumu
MXPA99001105A (en) Novel compounds and compositions for treating diseases associated with tryptase activity
NZ506614A (en) Compounds for treating diseases associated with tryptase activity
EP1368317B1 (en) Tryptase inhibitors
AU2002253035A1 (en) Tryptase inhibitors
LV12458B (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES
JP2005535685A (ja) トリプターゼ阻害剤としてのピロリジン誘導体